News
EU publishes consensus report on biosimilars
2013-09-06 The European Commission’s (EC’s) Enterprise and Industry Directorate-General has published a new report providing comprehensive information on the concept of biosimilars. The consensus information document… Read More »
Development of biosimilars for rheumatology
2013-09-04 In 2012, worldwide sales for the top three selling tumour necrosis factor (TNF) inhibitors reached US$20 billion. These biological treatments for arthritis are costing patients… Read More »
More UK patients affected by drug shortages in 2012
2013-09-02 The number of UK patients affected by shortages in brand-name medicines has increased during 2012, according to an online survey carried out by pharmacists’ organization Chemist+Druggist (C+D).… Read More »
Quality of generics in South Africa
2013-08-30 A study of the quality of generic medicines in South Africa has shown large differences in the perception and the actual quality of generics. The… Read More »
Research on clinical trial issues for biosimilars
2013-08-28 Period: September to December 2012 In order to demonstrate comparability between a biosimilar and its reference product, EMA recommends that the clinical trial should make… Read More »
Patients in US turn to generics to save money
2013-08-26 According to a new report released on 9 April 2013 by the US Centers for Disease Control and Prevention, adults in the US used several… Read More »
Efficacy, extrapolation and interchangeability of biosimilars
2013-08-23 Biosimilars have been available in Europe for more than seven years; despite this fact, physicians still have concerns about the use of biosimilars. Some of… Read More »
Cost savings from use of generic medicines in Ireland
2013-08-21 Ireland has one of the lowest usages of generics in the EU. However, in order to try to address this, the country introduced a new… Read More »
Quality, similarity and safety of biosimilars
2013-08-19 An abbreviated pathway for the approval of biosimilars was implemented in the EU in 2005. Despite biosimilars being available in Europe for more than seven… Read More »
Amgen’s biosimilar plans
2013-08-16 Amgen was one of the first companies to recognize the potential of modern biotechnology and this has made it the world’s largest independent biotechnology firm.… Read More »
